Pfizer’s Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) Receive FDA’s Approval for Transthyretin Amyloid Cardiomyopathy

 Pfizer’s Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) Receive FDA’s Approval for Transthyretin Amyloid Cardiomyopathy

Pfizer’s Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) Receive FDA’s Approval for Transthyretin Amyloid Cardiomyopathy

Shots:

  • The approval is based on P-III ATTR-ACT study assessing Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) vs PBO in patients with ATTR-CM
  • The P-III ATTR-ACT study results: @30mos. reduction in cardiovascular mortality & frequency of cardiovascular-related hospitalizations (30%, 32%)
  • Vyndaqel (80mg, qd) & Vyndamax (61mg, qd) are oral therapies, targeting transthyretin to stabilize tetramer of the transthyretin transport protein and slowing the formation of amyloid. Vyndaqel has received EU approval for ATTR-PN in 2011, FDA’s, EU’s & Japan’s ODD in 2012 & 2018 respectively

Click here to read full press release/ article | Ref: Pfizer | Image: Pfizercentreone

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post